Prognostic factors and treatment response in HER2-positive gastric cancer patients receiving trastuzumab deruxtecan: secondary analysis of the EN-DEAVOR study
Rattachement africain : jp, de, in. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background: EN-DEAVOR was a multi-institutional retrospective study evaluating the effectiveness and safety of trastuzumab deruxtecan (T-DXd) in gastric cancer patients. This secondary analysis investigated prognostic factors for real-world progression-free survival (rwPFS) and objective response rate (ORR) for T-DXd as third- or later-line treatment. Patients and methods: Patients aged ≥20 years with histopathologically confirmed human epidermal growth factor receptor 2 (HER2)-positive unresectable advanced or recurrent gastric or gastroesophageal junction adenocarcinoma, who had worsened after chemotherapy, were included. Patients received T-DXd as third- or later-line therapy between September 2020 and September 2021. Univariate and multivariate analyses identified prognostic factors for rwPFS and ORR. Results: Of the 307 patients, 75.6% were male and 69.1% were aged ≥65 years. The median duration of prior trastuzumab treatment was 6.5 months (range 0-81.5 months). Multivariate analysis showed HER2 immunohistochemistry (IHC) 3+ [hazard ratio (HR) 0.65, 95% confidence interval (CI) 0.49-0.86], intestinal type lesions (HR 0.59, 95% CI 0.43-0.79), modified Glasgow Prognostic Score (mGPS) 0 and 1 (HR 0.71, 95% CI 0.53-0.95), and longer duration of prior trastuzumab treatment (≥ median) (HR 0.75, 95% CI 0.58-0.97) as positive prognostic factors for rwPFS. Longer prior trastuzumab treatment was also a positive prognostic factor for ORR (odds ratio 2.02, 95% CI 1.13-3.63). Conclusions: Patients with clinical benefits from prolonged trastuzumab treatment are likely to benefit from T-DXd. Similarly, HER2 IHC 3+, intestinal type lesions, and better mGPS (0 or 1) are associated with longer rwPFS. However, T-DXd should not be withheld even in patients without these factors, as a median PFS of 3.42 months was observed in those with the shortest prior trastuzumab exposure.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Prognostic factors and treatment response in HER2-positive gastric cancer patients receiving trastuzumab deruxtecan: secondary analysis of the EN-DEAVOR study
- Date Crossref
- 01/06/2025
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Nagoya University Department of Gastroenterological Surgery pays non établi dans la noticeUniversité ou école supérieure
-
Osaka International Cancer Institute Department of Genetic Oncology pays non établi dans la noticeÉtablissement de santé
-
Nagoya Medical Center pays non établi dans la noticeÉtablissement de santé
-
Tohoku University Department of Clinical Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Kindai University Hospital pays non établi dans la noticeÉtablissement de santé
-
Kindai University Department of Medical Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Gifu University Hospital Cancer Center pays non établi dans la noticeÉtablissement de santé
-
Kyoto Prefectural University of Medicine Department of Surgery pays non établi dans la noticeUniversité ou école supérieure
-
Kyoto University Department of Biomedical Statistics and Bioinformatics pays non établi dans la noticeUniversité ou école supérieure
-
Aichi Cancer Center pays non établi dans la noticeÉtablissement de santé
-
Chiba Cancer Center pays non établi dans la noticeÉtablissement de santé
-
Saitama Cancer Center pays non établi dans la noticeÉtablissement de santé
Department of Gastroenterological Surgery — Nagoya University, Department of Genetic Oncology — Osaka International Cancer Institute et Nagoya Medical Center, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.